Skip to main content
Premium Trial:

Request an Annual Quote

Murex Pharmaceuticals, Partek, InforSense, CTC Laboratory Systems, Exludus Technologies, Columbia University, IBM, Bioinformatics.Org


Murex to Use GNS Modeling Technology for Cancer Drug Discovery

Murex Pharmaceuticals said this week that it will use modeling technology from Gene Network Sciences to develop cancer therapeutics.

Murex said it will use the GNS models to identify genes unique to an individual's malignancy and predict which pathways are most significant in a patient's cancer.

Based on this information, the company said it plans to design shRNA-based vaccines to stop the cancer growth.

"This marks the first time that biosimulation will be integral to the synthesis of therapies for cancer patients based on their individual gene expression data," said Colin Hill, GNS CEO, in a statement.

GNS scientists will work directly with Murex teams at the company's R&D facilities in Dallas and Carrollton, Texas.

Partek Signs Distributor, Two Customers in Israel

Partek said this week that Eisenberg Brothers will sell and support its statistical analysis and data-visualization software in Israel.

The distribution agreement includes Partek's Genomics Suite for microarray data, Discovery Suite for multi-dimensional non-microarray data, QSAR Solution for chemistry data, and Screener Solution for HTS screening data.

Separately, the company said that it had licensed its Partek Genomics Suite software to the Chaim Sheba Medical Center and the Weizmann Institute of Science.

The Tel Aviv, Israel-based Sheba Medical Center will use the software to statistically analyze data from its hemato-oncology studies. The Rehovot, Israel-based Weizmann Institute will use it to aid in research in a multitude of areas, including cancer, diabetes, nanoscience, and the environment.

CTC to Distribute InforSense Platform in Japan

InforSense said this week that CTC Laboratory Systems will distribute its KDE workflow platform in Japan.

Financial terms of the agreement were not disclosed.

CTCLS is a subsidiary of Itochu Techno-Science, a distributor and system integrator of computer systems and software in Japan.

Joseph Donahue, chief business officer of InforSense, said in a statement that the company is "experiencing strong demand" for its products in Japan.

Exludus Says Its Software Outperforms Network, Cluster File Systems on Blast Benchmarks

Exludus Technologies, a provider of data-transfer software, said this week that its RepliCator software has outperformed networked file systems and a dedicated cluster file system in NCBI-Blast benchmarks.

The company said it ran the benchmarks on the Niobe reference cluster of Opteron processors in Advanced Micro Devices' development center.

The tests were run at various node sizes on the full 5.4 GB human genome database and measured 3 kilobases of queries, per compute node, in each case.

The company said that RepliCator's run time on Blast with the full database using 64 nodes was 529 seconds — 2.7 times faster than the cluster file system, which came in at 1,462 seconds, and more than 10 times faster than NFS, which took 5,752 seconds.

At 128 nodes, RepliCator still ran the query in 529 seconds, which was 5 times faster than the cluster file system, which took 2,869 seconds. The NFS server case could not be run at 128 nodes, the company said.

Columbia's NCBC, IBM to Host DREAM Workshop in September

The National Center for Biomedical Computing at Columbia University, in collaboration with the IBM Computational Biology Center, will host a workshop for assessing methods for reverse engineering of biological circuits this fall, the organizations said this week.

The DREAM (Dialogue on Reverse Engineering Assessment Methods) workshop will be held at the Wave Hill Conference Center, New York, NY, Sept. 7-8.

As BioInform reported in February [BioInform 02-17-06], the organizers of the DREAM initiative aim to provide a forum for researchers to discuss a framework for evaluating experimental and computational tools used to reverse engineer biological pathways.

The workshop will address issues related to the identification of "gold standards" that could be used to test the accuracy of these methods, the organizers said in a statement this week. Further information on the workshop is available at

Bioinformatics.Org to Offer Online and On-Site Bioinformatics Training Courses

The non-profit Bioinformatics Organization said this week that it will now offer online and on-site training courses on open source bioinformatics software.

Online training will be free, but on-site courses will require a fee.

Bioinformatics.Org has scheduled its first on-site course for Sept. 19-20 in Cambridge, Mass. The course, which will instruct laboratory researchers on Perl and R, including BioPerl and Bioconductor, is $600 for students from commercial firms and $300 for academics. Further information is available at

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.